Aktuellt
SENASTE
Redeye is disappointed to learn that Irlab’s drug candidate mesdopetam, that targets levodopa induced dyskinesia, failed to show a statistically significant treatment effect in the primary endpoint in a phase IIb trial, although an effect was shown in a secondary endpoint. We give our initial comment.
LÄS MER
